Guggenheim Maintains Buy on Sionna Therapeutics, Raises Price Target to $60

Sionna Therapeutics

Sionna Therapeutics

SION

0.00

Guggenheim analyst Yatin Suneja maintains Sionna Therapeutics (NASDAQ: SION) with a Buy and raises the price target from $50 to $60.